Cargando…
Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
Parkinson disease is an age‐related disorder of the central nervous system principally due to loss of dopamine‐producing cells in the midbrain. Levodopa, in combination with carbidopa, is widely regarded as an effective treatment for the symptoms of Parkinson disease. A dose‐response relationship is...
Autores principales: | Mao, Zhongping Lily, Modi, Nishit B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066683/ https://www.ncbi.nlm.nih.gov/pubmed/26632091 http://dx.doi.org/10.1002/jcph.683 |
Ejemplares similares
-
Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013) -
Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015) -
Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019) -
Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
por: Morgan, John C., et al.
Publicado: (2018) -
Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)